Fox fears neuro backlash as bapi makes pharma think again
This article was originally published in Scrip
Executive Summary
The recent news that Pfizer, Janssen and Elan will kill development on bapineuzumab is particularly troubling for the Michael J. Fox Foundation, even thought the anti-beta-amyloid plaque monoclonal antibody was a prospective treatment for Alzheimer's, rather than Parkinson's, disease.